ULTRAGENYX PHARMACEUTICAL IN (RARE) Fundamental Analysis & Valuation

NASDAQ:RARE • US90400D1081

Current stock price

19.87 USD
-0.55 (-2.69%)
At close:
20.26 USD
+0.39 (+1.96%)
After Hours:

This RARE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. RARE Profitability Analysis

1.1 Basic Checks

  • RARE had negative earnings in the past year.
  • In the past year RARE has reported a negative cash flow from operations.
  • In the past 5 years RARE always reported negative net income.
  • In the past 5 years RARE always reported negative operating cash flow.
RARE Yearly Net Income VS EBIT VS OCF VS FCFRARE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -200M -400M -600M

1.2 Ratios

  • RARE has a Return On Assets (-37.53%) which is in line with its industry peers.
Industry RankSector Rank
ROA -37.53%
ROE N/A
ROIC N/A
ROA(3y)-38.69%
ROA(5y)-38.33%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
RARE Yearly ROA, ROE, ROICRARE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200 -200 400 600

1.3 Margins

  • Looking at the Gross Margin, with a value of 83.80%, RARE belongs to the top of the industry, outperforming 87.33% of the companies in the same industry.
  • RARE's Gross Margin has declined in the last couple of years.
  • RARE does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 83.8%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.14%
GM growth 5Y-3.03%
RARE Yearly Profit, Operating, Gross MarginsRARE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50K -100K -150K -200K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. RARE Health Analysis

2.1 Basic Checks

  • RARE does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, RARE has more shares outstanding
  • RARE has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for RARE is higher compared to a year ago.
RARE Yearly Shares OutstandingRARE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M
RARE Yearly Total Debt VS Total AssetsRARE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

2.2 Solvency

  • RARE has an Altman-Z score of -3.70. This is a bad value and indicates that RARE is not financially healthy and even has some risk of bankruptcy.
  • With a Altman-Z score value of -3.70, RARE perfoms like the industry average, outperforming 43.57% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -3.7
ROIC/WACCN/A
WACC8.16%
RARE Yearly LT Debt VS Equity VS FCFRARE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M -500M 1B

2.3 Liquidity

  • A Current Ratio of 2.48 indicates that RARE has no problem at all paying its short term obligations.
  • RARE has a worse Current ratio (2.48) than 70.63% of its industry peers.
  • RARE has a Quick Ratio of 2.34. This indicates that RARE is financially healthy and has no problem in meeting its short term obligations.
  • RARE has a worse Quick ratio (2.34) than 69.87% of its industry peers.
Industry RankSector Rank
Current Ratio 2.48
Quick Ratio 2.34
RARE Yearly Current Assets VS Current LiabilitesRARE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. RARE Growth Analysis

3.1 Past

  • The Earnings Per Share has been growing slightly by 7.89% over the past year.
  • RARE shows a strong growth in Revenue. In the last year, the Revenue has grown by 20.13%.
  • The Revenue has been growing by 19.95% on average over the past years. This is quite good.
EPS 1Y (TTM)7.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%7.19%
Revenue 1Y (TTM)20.13%
Revenue growth 3Y22.81%
Revenue growth 5Y19.95%
Sales Q2Q%25.55%

3.2 Future

  • The Earnings Per Share is expected to grow by 25.66% on average over the next years. This is a very strong growth
  • RARE is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 27.39% yearly.
EPS Next Y24.05%
EPS Next 2Y36.67%
EPS Next 3Y29.28%
EPS Next 5Y25.66%
Revenue Next Year12.73%
Revenue Next 2Y26.58%
Revenue Next 3Y28.44%
Revenue Next 5Y27.39%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
RARE Yearly Revenue VS EstimatesRARE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 1B 2B 3B
RARE Yearly EPS VS EstimatesRARE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 5 -5 10 -10

More info and screens

Find the best growth stocksShow best growing peers

1

4. RARE Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for RARE. In the last year negative earnings were reported.
  • Also next year RARE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RARE Price Earnings VS Forward Price EarningsRARE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RARE Per share dataRARE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6

4.3 Compensation for Growth

  • A more expensive valuation may be justified as RARE's earnings are expected to grow with 29.28% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.67%
EPS Next 3Y29.28%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. RARE Dividend Analysis

5.1 Amount

  • RARE does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

RARE Fundamentals: All Metrics, Ratios and Statistics

ULTRAGENYX PHARMACEUTICAL IN

NASDAQ:RARE (3/20/2026, 8:18:54 PM)

After market: 20.26 +0.39 (+1.96%)

19.87

-0.55 (-2.69%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-12
Earnings (Next)05-04
Inst Owners100.84%
Inst Owner Change-2.01%
Ins Owners3.23%
Ins Owner Change0.2%
Market Cap1.92B
Revenue(TTM)673.00M
Net Income(TTM)-575.00M
Analysts85.19
Price Target57.68 (190.29%)
Short Float %10.29%
Short Ratio3.83
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-29.78%
Min EPS beat(2)-43.75%
Max EPS beat(2)-15.82%
EPS beat(4)2
Avg EPS beat(4)-10.82%
Min EPS beat(4)-43.75%
Max EPS beat(4)11.68%
EPS beat(8)4
Avg EPS beat(8)-5.81%
EPS beat(12)5
Avg EPS beat(12)-5.47%
EPS beat(16)6
Avg EPS beat(16)-12.63%
Revenue beat(2)1
Avg Revenue beat(2)-1.46%
Min Revenue beat(2)-5.94%
Max Revenue beat(2)3.03%
Revenue beat(4)2
Avg Revenue beat(4)-1.74%
Min Revenue beat(4)-5.94%
Max Revenue beat(4)3.03%
Revenue beat(8)5
Avg Revenue beat(8)0.85%
Revenue beat(12)7
Avg Revenue beat(12)-0.46%
Revenue beat(16)8
Avg Revenue beat(16)-1.44%
PT rev (1m)-13.73%
PT rev (3m)-31.12%
EPS NQ rev (1m)6.01%
EPS NQ rev (3m)6.84%
EPS NY rev (1m)-12.09%
EPS NY rev (3m)-5.78%
Revenue NQ rev (1m)-4.99%
Revenue NQ rev (3m)-5.1%
Revenue NY rev (1m)-5.16%
Revenue NY rev (3m)-5.4%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.85
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-5.84
EYN/A
EPS(NY)-4.44
Fwd EYN/A
FCF(TTM)-5.04
FCFYN/A
OCF(TTM)-4.82
OCFYN/A
SpS6.96
BVpS-0.83
TBVpS-3.1
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -37.53%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 83.8%
FCFM N/A
ROA(3y)-38.69%
ROA(5y)-38.33%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.14%
GM growth 5Y-3.03%
F-Score4
Asset Turnover0.44
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 60%
Cap/Sales 3.12%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.48
Quick Ratio 2.34
Altman-Z -3.7
F-Score4
WACC8.16%
ROIC/WACCN/A
Cap/Depr(3y)98.69%
Cap/Depr(5y)330.02%
Cap/Sales(3y)5.82%
Cap/Sales(5y)15.7%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)7.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%7.19%
EPS Next Y24.05%
EPS Next 2Y36.67%
EPS Next 3Y29.28%
EPS Next 5Y25.66%
Revenue 1Y (TTM)20.13%
Revenue growth 3Y22.81%
Revenue growth 5Y19.95%
Sales Q2Q%25.55%
Revenue Next Year12.73%
Revenue Next 2Y26.58%
Revenue Next 3Y28.44%
Revenue Next 5Y27.39%
EBIT growth 1Y0.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year19.9%
EBIT Next 3Y27.7%
EBIT Next 5YN/A
FCF growth 1Y-12.17%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-12.51%
OCF growth 3YN/A
OCF growth 5YN/A

ULTRAGENYX PHARMACEUTICAL IN / RARE Fundamental Analysis FAQ

What is the ChartMill fundamental rating of ULTRAGENYX PHARMACEUTICAL IN (RARE) stock?

ChartMill assigns a fundamental rating of 2 / 10 to RARE.


Can you provide the valuation status for ULTRAGENYX PHARMACEUTICAL IN?

ChartMill assigns a valuation rating of 1 / 10 to ULTRAGENYX PHARMACEUTICAL IN (RARE). This can be considered as Overvalued.


How profitable is ULTRAGENYX PHARMACEUTICAL IN (RARE) stock?

ULTRAGENYX PHARMACEUTICAL IN (RARE) has a profitability rating of 1 / 10.


What is the financial health of ULTRAGENYX PHARMACEUTICAL IN (RARE) stock?

The financial health rating of ULTRAGENYX PHARMACEUTICAL IN (RARE) is 2 / 10.


Is the dividend of ULTRAGENYX PHARMACEUTICAL IN sustainable?

The dividend rating of ULTRAGENYX PHARMACEUTICAL IN (RARE) is 0 / 10 and the dividend payout ratio is 0%.